Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments
Selecta Biosciences, Ginkgo Bioworks Join Forces To Develop Rare Disease Treatments
SELECTA生物科學公司和銀杏生物工程公司聯手開發罕見疾病治療藥物
- Selecta Biosciences Inc (NASDAQ:SELB) and Ginkgo Bioworks Holdings Inc (NYSE:DNA) have collaborated to design novel and improved therapeutic potential enzymes for orphan and rare diseases.
- The partnership will leverage Ginkgo's cell programming platform and Selecta's ImmTOR platform to create potentially transformative enzymatic therapies.
- Selecta has gained rights to develop and commercialize select therapeutic enzymes to treat select auto-immune diseases.
- Under the terms of the collaboration, Ginkgo is eligible for upfront R&D fees and milestones, including certain milestone payments in Selecta common stock, clinical and commercial milestone payments of up to $85M in cash.
- Related: Selecta In-Licenses Rights To IgG Protease Platform.
- Price Action: SELB shares are up 7.24% at $3.83, and DNA shares are up 6.09% at $15.15 during the market session on the last check Tuesday.
- Selecta生物科學公司(納斯達克股票代碼：SELB)和銀杏生物工程控股有限公司紐約證券交易所股票代碼：DNA)合作設計了針對孤兒和罕見疾病的新型和改進的潛在治療酶。
- 這一合作關係將利用銀杏的細胞編程平台和Selecta的ImmTOR平台來創造潛在的變革性酶療法。
- SELECTA已獲得開發和商業化用於治療特定自身免疫性疾病的精選治療酶的權利。
- 根據合作條款，銀杏有資格獲得預付研發費用和里程碑，包括某些里程碑付款，包括Selecta普通股、臨牀和商業里程碑付款，最高可達8500萬美元現金。
- 相關： Selecta In-License Right to IgG Protease Platform(選擇IgG蛋白酶平台許可權).
- 價格行動：週二尾盤，SELB股價上漲7.24%，至3.83美元，DNA股價上漲6.09%，至15.15美元。